Lecture image placeholder

Premium content

Access to this content requires a subscription. You must be a premium user to view this content.

Monthly subscription - $9.99Pay per view - $4.99Access through your institutionLogin with Underline account
Need help?
Contact us
Lecture placeholder background
VIDEO DOI: https://doi.org/10.48448/qmy3-ey61

technical paper

ENDO 2020

June 10, 2020

Virtual, United States

Increasing Patient Participation in Research: Strategies for Success

Please log in to leave a comment

Downloads

Transcript English (automatic)

Next from ENDO 2020

The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Results from A Multiple-Dose Phase 2 Study
technical paper

The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Results from A Multiple-Dose Phase 2 Study

ENDO 2020

+5Nagdeep GiriRobert FarberRichard Auchus
Richard Auchus and 7 other authors

10 June 2020

Similar lecture

Modern Management of the Patient With Paget's Disease
technical paper

Modern Management of the Patient With Paget's Disease

ENDO 2021

21 March 2021

Stay up to date with the latest Underline news!

Select topic of interest (you can select more than one)

PRESENTATIONS

  • All Lectures
  • For Librarians
  • Resource Center
  • Free Trial
Underline Science, Inc.
1216 Broadway, 2nd Floor, New York, NY 10001, USA

© 2023 Underline - All rights reserved